Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab
-
- Okuhira Hisako
- Department of Dermatology, Wakayama Medical University
-
- Yamamoto Yuki
- Department of Dermatology, Wakayama Medical University
-
- Inaba Yutaka
- Department of Dermatology, Wakayama Medical University
-
- Kunimoto Kayo
- Department of Dermatology, Wakayama Medical University
-
- Mikita Naoya
- Department of Dermatology, Wakayama Medical University
-
- Ikeda Takaharu
- Department of Dermatology, Wakayama Medical University
-
- Kaminaka Chikako
- Department of Dermatology, Wakayama Medical University
-
- Minami Yoshimi
- Department of Dermatology, Wakayama Medical University
-
- Kanazawa Nobuo
- Department of Dermatology, Wakayama Medical University
-
- Furukawa Fukumi
- Department of Dermatology, Wakayama Medical University
-
- Jinnin Masatoshi
- Department of Dermatology, Wakayama Medical University
この論文をさがす
抄録
<p>Biomarkers to distinguish patients with advanced melanoma responsive to nivolumab are of great interest. Therefore, we examined the possibility that laboratory data of daily blood examination become novel biomarkers. Laboratory data of 16 melanoma patients who were treated with nivolumab were retrospectively analyzed. Patients were classified as responder group or non-responder group. Examined were: white blood cell count (WBC), absolute lymphocyte counts (ALC), absolute neutrophil count (ANC), absolute monocyte count (AMC), absolute eosinophil count (AEC), and absolute basophil count (ABC), as well as levels of lactate dehydrogenase (LDH), C-reactive protein (CRP), one hour value of erythrocyte sedimentation rate (ESR), and 5-S-cysteinydopa (5-S-CD). Responder group showed significantly higher baseline levels of ESR or CRP and significantly lower ALC level before nivolumab treatment. Additionally, nivolumab treatment decreased the levels of CRP, ESR, and ANC, while it increased ALC level in the responder group. CRP was the most effective in distinguishing responder group from non-responder group both before and during treatment, according to the receiver operating characteristic (ROC) curve. We firstly showed that ESR is also the baseline biomarker of the efficacy of nivolumab. Furthermore, we confirmed that CRP is useful to predict the efficacy both before and during the treatment, and suggested that CRP is the most effective biomarker among daily blood examination by using ROC curve analysis. There is a possibility that nivolumab treatment may be more effective for malignant melanoma with stronger inflammation.</p>
収録刊行物
-
- BioScience Trends
-
BioScience Trends 12 (4), 412-418, 2018-08-31
特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会
